Leerink Partnrs Has Bullish Outlook for KALV Q3 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Investment analysts at Leerink Partnrs upped their Q3 2025 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a report released on Monday, November 4th. Leerink Partnrs analyst J. Schwartz now forecasts that the specialty pharmaceutical company will post earnings of $0.81 per share for the quarter, up from their prior forecast of ($0.92). The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.19) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($1.66) EPS and FY2026 earnings at ($2.26) EPS.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.04.

Other equities analysts have also issued reports about the stock. Needham & Company LLC reissued a “buy” rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV opened at $11.41 on Thursday. KalVista Pharmaceuticals has a one year low of $7.21 and a one year high of $16.88. The company has a market capitalization of $493.14 million, a price-to-earnings ratio of -3.23 and a beta of 0.92. The company’s 50-day simple moving average is $11.44 and its two-hundred day simple moving average is $12.08.

Insider Activity at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 7,352 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $12.19, for a total transaction of $89,620.88. Following the transaction, the chief executive officer now directly owns 250,800 shares of the company’s stock, valued at approximately $3,057,252. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Paul K. Audhya sold 2,135 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the transaction, the insider now directly owns 83,745 shares of the company’s stock, valued at $1,038,438. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,352 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $12.19, for a total transaction of $89,620.88. Following the sale, the chief executive officer now directly owns 250,800 shares in the company, valued at approximately $3,057,252. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,804 shares of company stock valued at $372,112 over the last 90 days. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC purchased a new position in KalVista Pharmaceuticals in the 3rd quarter worth $126,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of KalVista Pharmaceuticals by 114.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 22,949 shares of the specialty pharmaceutical company’s stock valued at $266,000 after purchasing an additional 12,245 shares during the period. Quest Partners LLC purchased a new position in shares of KalVista Pharmaceuticals in the third quarter worth about $175,000. Emerald Advisers LLC lifted its holdings in shares of KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares during the period. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in shares of KalVista Pharmaceuticals by 23.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after purchasing an additional 121,615 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).